P-108 - Systematic evaluation of serum inflammatory markers for prognostication of hepatocellular carcinoma (HCC)

Date 04 July 2015
Event WorldGI 2015
Session Posters
Topics Hepatobiliary Cancers
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter S. Chan
Citation Annals of Oncology (2015) 26 (suppl_4): 1-100. 10.1093/annonc/mdv233
Authors S. Chan1, F. Mo2, A. Chan3, C. Chan1, K. Mok1, C. Liu1, N. Tang1, W. Yeo2
  • 1The Chinese University of Hong Kong, Shatin/CN
  • 2Chinese University of Hong Kong, Hong Kong/CN
  • 3Department of Chemical Pathology, Shatin/CN



It is evident that systemic inflammation plays a prognostic role in HCC. Different markers including C-reactive protein (CRP) and various cytokines have been shown to be prognostic factors for HCC. However, there have been no studies that simultaneously and comprehensively evaluate the prognostication of serum inflammatory factors together.


From 2007 to 2011, our group constituted a prospective cohort of patients with newly confirmed diagnosis of HCC. All patients consented to blood taking for storage for future purposes. All clinical information including tumor staging was collected at the time of consent. The serum samples were subject to a multiplex cytokine assays testing 43 inflammatory cytokines and C-reactive protein (Eve Technologies, Alberta, Canada). All patients were followed up according to standard local practice. The prognostications of baseline level of the serum inflammatory markers are evaluated by univariate and multivariate analyses.


Serum samples from 600 patients were analyzed, of which 560 of them are eligible for analyses. The median follow-up is 39 months and the median overall survival is 8.6 months (7.3-9.9 months). The median age is 60 years (Range 18-88); 443 pts (79.1%) and 74 (13.2%) have hepatitis B and C virus infection, respectively. The mean tumor diameter was 8.55cm. The BCLC Stage distribution of 0/A, B, C and D is 15.7%, 23.6%, 55.2% and 5.5%, respectively. Total 102 patients underwent treatment of curative intent (64 surgery; 38 locoablation) while the remaining patients (n = 458) received treatment of palliative intent. In univariate analyses, TGFa, Factalkine, IFNa2, INFɣ, Chemokine (C-X-C motif) ligand 1, Macrophage-derived chemokine (MDC), IL-6, IL-7, IL-8, IL-10, IL-17A, IP-10, MIP-1α, TNF-α, VEGF-A, CRP are all prognostic factors for overall survival. Multivariate analyses identified four serum inflammatory markers, namely IL-8, CRP, IP-10 and MDC to be independent prognostic factors for HCC (all p < 0.0001). The prognostications of these markers are independent of BCLC staging system (Table 1).


Four serum markers reflective inflammation, namely IL-8, CRP, IP-10 and MDC are independent prognostic factors. This panel of markers have additional prognostic information on existing staging system. (Supported by Hong Kong Research Grants Council General Research Fund [No. 462013]).

Table: P-108 Multivariate analysis on prognostication of serum inflammatory markers and BCLC system